Home  |  Contact

Cellosaurus RL95-2 (CVCL_0505)

[Text version]

Cell line name RL95-2
Synonyms RL-95-2; RL-952; RL952; RL95
Accession CVCL_0505
Resource Identification Initiative To cite this cell line use: RL95-2 (RRID:CVCL_0505)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: TCGA-110-CL cell line panel.
Doubling time: 22 hours (PubMed=1541432).
Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Heterozygous for HRAS p.Gln61His (c.183G>T) (ATCC; Cosmic-CLP).
Heterozygous for PTEN p.Asn323fs*2 (c.968_969insA) and p.Asn323fs*21 (c.968delA) (PubMed=20944090).
Heterozygous for TP53 p.Val73fs*50 (c.216delC) and p.Val218del (c.652_654delGTC) (PubMed=9887230; Cosmic-CLP).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0.33
East Asian, North1.49
East Asian, South0
South Asian1.52
European, North68.38
European, South28.28
Disease Endometrial adenosquamous carcinoma (NCIt: C114656)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 65Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,11
D2S133822,23
D3S135814,16
D5S81810,11
D7S82010
D8S117910,14
D13S3178,12
D16S53911,13
D18S5110,14
D19S43315
D21S1128,29
FGA20,22
Penta D9
Penta E5,11
TH019,9.3
TPOX8
vWA16,20

Run an STR similarity search on this cell line
Web pages http://tcpaportal.org/mclp/
http://www.cellresource.cn/fdetail.aspx?id=887
http://www.cellresource.cn/fdetail.aspx?id=1705
Publications

PubMed=6339371; DOI=10.1007/BF02618053
Way D.L., Grosso D.S., Davis J.R., Surwit E.A., Christian C.D.
Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture.
In Vitro 19:147-158(1983)

PubMed=2436984; DOI=10.1016/0090-8258(87)90286-1
Noumoff J., Haydock S.W., Sachdeva R., Heyner S., Pritchard M.L.
Characteristics of cell lines derived from normal and malignant endometrial tissue.
Gynecol. Oncol. 27:141-149(1987)

PubMed=1541432; DOI=10.1016/0090-8258(92)90045-K
Rantanen V., Grenman S.E., Kulmala J., Salmi T., Grenman R.
Radiation sensitivity of endometrial carcinoma in vitro.
Gynecol. Oncol. 44:217-222(1992)

PubMed=7798295; DOI=10.1007/BF01194268
Rantanen V., Grenman S., Kulmala J., Alanen K., Lakkala T., Grenman R.
Sublethal damage repair after fractionated irradiation in endometrial cancer cell lines tested with the 96-well plate clonogenic assay.
J. Cancer Res. Clin. Oncol. 120:712-716(1994)

PubMed=8123477; DOI=10.1038/bjc.1994.87
Rantanen V., Grenman S.E., Kulmala J., Grenman R.
Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines.
Br. J. Cancer 69:482-486(1994)

PubMed=9887230; DOI=10.1006/gyno.1998.5194
Rantanen V., Grenman S.E., Kurvinen K., Hietanen S., Raitanen M., Syrjanen S.
p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines.
Gynecol. Oncol. 71:352-358(1998)

PubMed=12893190; DOI=10.1016/s0090-8258(03)00335-4
Tanaka R., Saito T., Ashihara K., Nishimura M., Mizumoto H., Kudo R.
Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.
Gynecol. Oncol. 90:297-304(2003)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20944090; DOI=10.1126/scitranslmed.3001538
Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R., Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A., Lord C.J., Ashworth A., Reis-Filho J.S.
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Sci. Transl. Med. 2:53ra75-53ra75(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574-3574(2019)

Cross-references
Cell line collections ATCC; CRL-1671
BCRC; 60103
BCRJ; 0366
CCTCC; GDC0113
KCB; KCB 2013033YJ
Cell line databases/resources CCLE; RL952_ENDOMETRIUM
CCRID; 3131C0001000700198
CCRID; 3142C0001000000119
Cell_Model_Passport; SIDM01088
Cosmic-CLP; 930082
DepMap; ACH-000965
IGRhCellID; RL952
LINCS_LDP; LCL-1506
Lonza; 1501
Ontologies BTO; BTO:0004491
CLO; CLO_0008830
EFO; EFO_0002320
MCCL; MCC:0000402
Biological sample resources BioSample; SAMN03473219
BioSample; SAMN10987787
Chemistry resources ChEMBL-Cells; CHEMBL3308843
ChEMBL-Targets; CHEMBL2366168
GDSC; 930082
PharmacoDB; RL952_1319_2019
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM374977
GEO; GSM375436
GEO; GSM844677
GEO; GSM887542
GEO; GSM888625
GEO; GSM1670382
Other Wikidata; Q54950589
Polymorphism and mutation databases Cosmic; 713477
Cosmic; 713489
Cosmic; 809132
Cosmic; 846175
Cosmic; 871556
Cosmic; 889117
Cosmic; 930082
Cosmic; 980637
Cosmic; 1007165
Cosmic; 1066226
Cosmic; 1070808
Cosmic; 1102377
Cosmic; 1177623
Cosmic; 1223487
Cosmic; 1576464
Cosmic; 1622899
Cosmic; 1696756
Cosmic; 2030481
Cosmic; 2301551
Cosmic; 2646617
IARC_TP53; 1114
LiGeA; CCLE_166
Entry history
Entry creation04-Apr-2012
Last entry updated19-Dec-2019
Version number29